Tecentriq
Tecentriq Uses, Dosage, Side Effects, Food Interaction and all others data.
Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells suppresses cytotoxic T-cell activity through the inhibition of T-cell proliferation and cytokine production. PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells, and can contribute to the inhibition of the antitumor immune response in the microenvironment. Tecentriq is an Fc-engineered humanized immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors, releasing PD-L1 / PD-1 pathway-mediated inhibition of the immune response, including reactivating the antitumor immune response. Tecentriq leaves the PD-L2/PD-1 interaction intact. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in decreased tumor growth
Tecentriq is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This drug has a long duration of action as it is usually given every 3-4 weeks. Tecentriq should not be used in patients with immune mediated penumonitis, hepatitis, colitis, and some endocrinopathies.
| Trade Name | Tecentriq |
| Availability | Prescription only |
| Generic | Atezolizumab |
| Atezolizumab Other Names | Atezolizumab |
| Related Drugs | Opdivo, methotrexate, Keytruda, pembrolizumab, doxorubicin, cisplatin, Tagrisso, Avastin, bevacizumab, nivolumab |
| Weight | 1200mg/vial, , 60mg/ml, 1200mg/20ml, 840mg/14ml |
| Type | Injection, Iv Infusion, Solution, Concentrate, Intravenous Solution |
| Weight | 145000.0 Da |
| Protein binding | Monoclonal antibodies are not expected to bind to proteins in plasma they are not designed to target. |
| Groups | Approved, Investigational |
| Therapeutic Class | Anti neoplastic preparations, Vaccines, Anti-sera & Immunoglobulin |
| Manufacturer | Roche Bangladesh Ltd,, Roche Products Limited |
| Available Country | India, Bangladesh, United Kingdom, Australia, Saudi Arabia, United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Tecentriq is used for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC):
- After prior chemotherapy, or
- Who are considered cisplatin ineligibleand whose tumours have a PD-L1 expression ≥ 5%, or
- Who are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression.
Pediatric use: The safety and efficacy of Tecentriq in children and adolescents below 18 years of age have not been established.
Geriatric use: Based on a population pharmacokinetic analysis, no dose adjustment of Tecentriq is required in patients ≥ 65 years of age
Renal impairment: Based on a population pharmacokinetic analysis, no dose adjustment is required in patients with renal impairment
Hepatic impairment: Based on a population pharmacokinetic analysis, no dose adjustment is required for patients with mild hepatic impairment. There are no data in patients with moderate or severe hepatic impairment
Tecentriq is also used to associated treatment for these conditions: Metastatic Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Urothelial carcinoma ureter metastatic, Locally advanced Urothelial Carcinoma
How Tecentriq works
Tecentriq is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity.
Dosage
Tecentriq dosage
General: Tecentriq must be administered as an intravenousinfusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus. Substitution by any other biological medicinal product requires the consent of the prescribing physician. The initial dose of Tecentriq must be administered over 60 minutes. If the first infusion is tolerated all subsequent infusions may be administered over 30 minutes. The recommended dose of Tecentriq is either:
- 1200 mg administered by IV infusion every 3 weeks or
- 1680 mg administered by IV infusion every 4 weeks.
Toxicity
Most common adverse reactions (≥ 20% of patients) included: fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation.
Overdose data for atezolizumab is scarce but the most common adverse reactions are fatigue, nausea, cough, dyspnea, decreased appetite, alopecia, constipation, diarrhea, peripheral neuropathies, anemia, headache, neutropenia, and vomiting.
Precaution
Immune-related pneumonitis: Cases of pneumonitis, including fatal cases, have been observed in clinical trials with Tecentriq. Patients should be monitored for signs and symptoms of pneumonitis.
Immune-related hepatitis: Cases of hepatitis, some leading to fatal outcomes, have been observed in clinical trials with Tecentriq. Patients should be monitored for signs and symptoms of hepatitis. Monitor aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin prior to and periodically during treatment with Tecentriq. Consider appropriate management of patients with abnormal liver function tests (LFTs) at baseline.
Immune-related colitis: Cases of diarrhea or colitis have been observed in clinical trials with Tecentriq. Patients should be monitored for signs and symptoms of colitis.
Immune-related endocrinopathies: Hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, and type 1 diabetes mellitus, including diabetic ketoacidosis, have been observed in clinical trials with Tecentriq. Patients should be monitored for clinical signs and symptoms of endocrinopathies. Monitor thyroid function prior to and periodically during treatment with Tecentriq. Consider appropriate management of patients with abnormal thyroid function tests at baseline. Patients with abnormal thyroid function tests who are asymptomatic may receive Tecentriq.
Food Interaction
No interactions found.Tecentriq Drug Interaction
Unknown: paclitaxel protein-bound, charcoal, aspirin, ubiquinone, docusate, prochlorperazine, ubiquinone, apixaban, sodium iodide, metoprolol, magnesium hydroxide, morphine, esomeprazole, insulin aspart/insulin aspart protamine, acetaminophen, bioflavonoids, paclitaxel, metoprolol, cholecalciferol, levocetirizine
Tecentriq Disease Interaction
Major: endocrinopathies, hepatitis, infections, meningitis, neuropathy, pancreatitisModerate: colitis, liver disease, pneumonitis, renal impairment
Volume of Distribution
The volume of distribution of atezolizumab is 6.91L.
Elimination Route
Pharmacokinetic analysis was performed in patients with metastatic urothelial carcinoma. In these patients, the AUC was 2.19-2.73day*µg/mL/mg, the Cmax was 0.27-0.35µg/mL/mg, and the Cmin was 0.004-0.008µg/mL/mg.
Half Life
The half life of atezolizumab is 27 days.
Clearance
The clearance of atezolizumab is 0.200L/day.
Elimination Route
Tecentriq is not renally excreted.
Pregnancy & Breastfeeding use
There are no clinical studies of Tecentriq in pregnant women. Tecentriq is not recommended during pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetus
It is not known whether Tecentriq is excreted in human breast milk. No studies have been conducted to assess the impact of Tecentriq on milk production or its presence in breast milk.Asthe potential for harm to the nursing infant is unknown,a decision must be madeto either discontinue breast-feeding ordiscontinue Tecentriqtherapy.
Contraindication
Tecentriq is contraindicated in patients with a known hypersensitivity to atezolizumab or any of the excipients.
Acute Overdose
There is no information on overdose with Tecentriq
Storage Condition
Store at 2°C-8°C. Tecentriq should be protected from light. Do not freeze. Do not shake.
Innovators Monograph
You find simplified version here Tecentriq
